Stock events for Rigel Pharmaceuticals, Inc. (RIGL)
In March 2026, Rigel reported its fourth-quarter and full-year 2025 financial results, projecting a revenue decline for 2026 due to a decrease in contract revenue. In January 2026, Rigel provided a business update and its 2026 outlook, forecasting total revenue of approximately $275 million to $290 million. In February 2026, Director Walter H. Moos sold 4,000 shares of RIGL stock. Analyst ratings and price targets saw adjustments from Jefferies Financial Group, Wall Street Zen, and Cantor Fitzgerald. In November 2025, Rigel announced the publication of final 5-year data on REZLIDHIA. In December 2025, Rigel presented updated data from the ongoing Phase 1b study evaluating R289. As of February 16, 2026, Rigel's stock had surged 59% over the past year.
Demand Seasonality affecting Rigel Pharmaceuticals, Inc.’s stock price
There is no direct information available to indicate demand seasonality for Rigel Pharmaceuticals' products. The diseases these products treat are generally not considered seasonal conditions. The available search results discussing seasonality for RIGL refer to stock price seasonality rather than product demand.
Overview of Rigel Pharmaceuticals, Inc.’s business
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and providing novel small-molecule drugs. The company operates within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical industries, focusing on therapeutic areas such as hematologic disorders, cancer, and rare immune diseases. Rigel's portfolio includes TAVALISSE for chronic immune thrombocytopenia, REZLIDHIA for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation and GAVRETO for non-small cell lung cancer and thyroid cancer. The company also has clinical programs including an IRAK1/4 inhibitor program (R289) and a RIPK1 inhibitor in collaboration with Eli Lilly.
RIGL’s Geographic footprint
Rigel Pharmaceuticals primarily develops and provides therapies in the United States. The company also engages with partners to bring its products to markets outside of the U.S., indicating an international presence through collaborations.
RIGL Corporate Image Assessment
Rigel Pharmaceuticals' brand reputation appears to be generally positive, driven by the strong financial performance of its marketed products and advancements in its clinical pipeline. The company reported record net product sales and net income for 2025, with Tavalisse being a primary growth engine. Positive data from the Phase 1b study of R289 and the publication of 5-year data for REZLIDHIA also contribute to a favorable reputation. Analyst upgrades and increased price targets suggest a positive perception within the investment community.
Ownership
Rigel Pharmaceuticals, Inc. has a significant portion of its shares held by institutional investors, ranging from approximately 66.23% to 87.14% of the total stock. Major institutional owners include BlackRock, Inc., State Street Corp, Vanguard Group Inc, Armistice Capital, Llc, Goldman Sachs Group Inc, LSV Asset Management, Renaissance Technologies Llc, Acadian Asset Management Llc, Millennium Management Llc, D. E. Shaw & Co., Inc., Morgan Stanley, Soleus Capital Master Fund, L.P. and Marshall Wace LLP. Key individual owners include Raul R. Rodriguez, Dean L. Schorno, David A. Santos and Walter H. Moos.
